BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25489684)

  • 1. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
    Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
    Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing perceptions in pulmonary hypertension.
    Gerges C; Lang IM
    Lancet Respir Med; 2014 Jan; 2(1):21-3. PubMed ID: 24461891
    [No Abstract]   [Full Text] [Related]  

  • 7. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pulmonary arterial hypertension--a rare form of pulmonary hypertension].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(21):p21. PubMed ID: 20509110
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.
    Zhang Y; Yu X; Jin Q; Luo Q; Zhao Z; Zhao Q; Yan L; Liu Z
    Heart Fail Rev; 2019 Nov; 24(6):949-965. PubMed ID: 31044326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary hypertension].
    Kovacs G; Olschewski H
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC
    Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The current pharmacotherapy of pulmonary arterial hypertension].
    Betkier-Lipińska K; Ryczek R; Cwetsch A
    Pol Merkur Lekarski; 2015 Jan; 38(223):34-8. PubMed ID: 25763586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Belik J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macitentan for the treatment of pulmonary arterial hypertension.
    Kholdani CA; Fares WH; Trow TK
    Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and advancing treatments for pulmonary arterial hypertension in childhood.
    Zijlstra WM; Ploegstra MJ; Berger RM
    Expert Rev Respir Med; 2014 Oct; 8(5):615-28. PubMed ID: 25047735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension.
    Dowdall M
    Future Cardiol; 2014 Mar; 10(2):163. PubMed ID: 24883440
    [No Abstract]   [Full Text] [Related]  

  • 19. [Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].
    Sommer N; Richter MJ; Tello K; Grimminger F; Seeger W; Ghofrani HA; Gall H
    Internist (Berl); 2017 Sep; 58(9):937-957. PubMed ID: 28819824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
    Bai Y; Sun L; Hu S; Wei Y
    Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.